Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are more effective in reducing the signs and symptoms of RA and that can sustain efficacy over time are needed. Novel agents able to demonstrate strong efficacy in these attributes will have substantial influence on physicians’ prescribing decisions for RA. We provide quantitative insight into U.S. and European rheumatologists’ perceptions of key treatment drivers and goals and the current level of unmet need in this indication. We analyze the commercial opportunities in the treatment of RA and discuss how emerging therapies can capitalize on these opportunities. Additionally, using an adaptive choice-based conjoint analysis, we offer an assessment of trade-offs, across clinical attributes and price, that can impact physicians’ prescribing likelihood and preference share of select target product profiles.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in December 2016.
Key companies: AbbVie, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Incyte, Janssen, Pfizer, Roche
Key drugs: Humira, Remicade, Rituxan/MabThera, Orencia, Actemra/RoActemra, Xeljanz, baricitinib